ABSTRACT
INTRODUCTION
generally occurs as the first in this sequence of events and is followed by a compensatory increase in insulin secretion by the pancreatic beta-cells, thereby maintaining close to normal plasma glucose levels. 4, 6 In those individuals who ultimately develop T2DM a combination of beta-cell dysfunction and a reduction in beta-cell mass culminates in decreasing insulin secretion and associated hyperglycemia. By the time T2DM is diagnosed 50% of the beta-cell function may already be lost. 7 In addition, excessive and inappropriate glucagon secretion is commonly observed in T2DM, which might exacerbate hyperglycemia and complicate management of the disorder. 8 As a result of the deleterious effects of chronic hyperglycemia the majority of individuals with T2DM will experience microvascular and/or macrovascular complications. These include diabetic retinopathy, nephropathy, neuropathy, peripheral arterial disease, stroke, and coronary artery disease. 9 The ultimate goal of any pharmacological intervention in T2DM is to limit microvascular and potentially macrovascular complications by maintaining plasma glucose levels within a relatively normal range. 10 This link between glycemic control and vascular complications was highlighted in the UK Prospective Diabetes Study (UKPDS).
Glycated hemoglobin A 1c (HbA 1c ) levels were used as a determinant of glycemic control, and for every 1% reduction in HbA 1c it was estimated that there would be an associated 37% risk reduction for microvascular complications and a 21% reduction in diabetes-related deaths.
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CURRENTLY AVAILABLE TREATMENTS
There is a well-established association between weight gain and T2DM, and the majority of • Metformin is generally recommended as the first line of treatment in T2DM. It decreases hepatic glucose production, improves glucose clearance through an improvement of hepatic insulin sensitivity, decreases fatty acid oxidation, and increases glucagon-like peptide 1 (GLP-1; an endogenous peptide secreted from the gastrointestinal tract and a potent stimulator of glucose-dependent insulin release) levels.
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• Sulfonylureas, such as glimepiride and glipizide, inhibit pancreatic beta-cell K ATP channels and enhance insulin secretion.
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• Thiazolidinediones (TZDs), such as rosiglitazone and pioglitazone, are peroxisome proliferator-activated receptorgamma agonists. They increase the sensitivity of muscle, fat, and liver to endogenous and exogenous insulin indirectly reducing hepatic glucose production by altering adipose tissue lipid metabolism.
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• Meglitinides, such as repaglinide and nateglinide, also bind to the beta-cell K ATP channel, albeit at a different site, and stimulate insulin secretion.
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• GLP-1 mimetics, including exenatide and in the kidney where it is exclusively found in the brush border membrane of the S1 segment of the proximal tubule. 25, 27, 28 The remainder of the glucose is reabsorbed from the filtrate in the distal S3 segment of the renal proximal tubule by the high-affinity, low-capacity glucose transporter sodium glucose cotransporter 1, SGLT1 ( Figure 1A) . 29, 30 However, while SGLT2
is predominantly expressed in the kidney, SGLT1 is also highly expressed in the small intestine, where it is involved in the transport of glucose across the brush border membrane.
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In the renal tubule an electrochemical gradient generated by the Na + /K + ATPase located in the 
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Dapaglifl ozin is furthest along in development and is currently in phase 3 trials. For the remainder of this article we will review the preclinical and clinical data available for dapaglifl ozin.
DAPAGLIFLOZIN
Preclinical Studies
In preclinical studies dapagliflozin exhibited 
Clinical Efficacy in T2DM Patients
Healthy subjects administered dapagliflozin (2.5-100 mg once daily) for up to 2 weeks exhibited no change in glycemic parameters. From Diabetes Care, Vol. 32, 2009; 1656 -1662 Reprinted with permission from The American Diabetes Association. 
Tolerability and Side Effects
In T2DM patients adverse events observed in the dapagliflozin treatment and placebo groups were similar in frequency and were generally mild in nature whether for patients who were treatment naïve or for those receiving ongoing metformin or insulin plus insulin sensitizer therapy. [40] [41] [42] [43] [44] [45] [46] [47] Few cases of hypoglycemia were observed and these were generally mild, self-limiting, and occurred with a similar frequency in the placebo group; none were severe.
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A mild diuretic effect of dapagliflozin was In the 24-week studies, signs and symptoms suggestive of genital infection were reported in up to 13% of T2DM patients who were either treatment naïve or who were inadequately controlled with metformin as compared with 1.3% and 5% in the respective placebo groups. 46, 47 No increased rate of discontinuation occurred as a result of these signs and symptoms suggestive of UTIs or genital infections. 39, [41] [42] [43] [46] [47] [48] to have an acceptable safety profile they may have the potential to be administered alone or in combination with metformin or insulin.
The lack of long-term (including cardiovascular) safety data and other outcome data may limit their use initially to specific/defined low-risk patient groups.
CONCLUSION
In conclusion, dapagliflozin has the potential to be a useful addition to currently available antidiabetes treatments as it lowers fasting and postprandial glucose levels, improves glycemic control, and causes weight loss with a low risk of hypoglycemia. However, data regarding longterm safety including urinary tract infection, genital infection, and cardiovascular safety are needed, and its place in the algorithm of T2DM management is still to be determined. 
